首页 > 最新文献

European annals of allergy and clinical immunology最新文献

英文 中文
Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey. 慢性鼻炎伴鼻息肉和生物制剂:ARIA-ITALY 调查。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-27 DOI: 10.23822/EurAnnACI.1764-1489.338
C Lombardi, G Passalacqua, F Menzella, R F Mauritz Canevari, G Danesi, A M Pusateri, M Carone, C Vancheri, F Di Marco, C Micheletto, G Manzotti, M Di Gioacchino, M B Bilò, M Gelardi, G Senna, G W Canonica

Summary: Background. Chronic rhinosinusitis (CRS) is an inflammatory disease that affects the nasal mucosa and the paranasal sinuses. CRS can be associated by nasal polyposis (CRSwNP phenotype) in up to 30% of patients and it is frequently associated with bronchial asthma. CRSwNP shows predominantly an underlying activation of type 2 inflammatory pathways with the involvement of eosinophils, IgE, interleukin (IL)-4, IL-5 and IL-13. Biological drugs that target these inflammatory cytokines are currently a therapeutic option recognized by guidelines for the treatment of uncontrolled form of the disease. Methods. As part of the activity of the "ARIA-Italy" working group, a panel of 255 Italian Ear, Nose and Throat (ENT) specialists, pneumologists and immuno-allergologists actively participated in this national survey and answered a series of questions geared toward understanding the main criteria for patient characterization and therapeutic decision, highlighting multidisciplinarity, and the implementation of the management of CRSwNP patients, as a part of the precision medicine concept and the appropriate use of the biologicals. Results. Two hundred and fifty-five experts and specialists participated in the survey. Conclusions. The results of this survey obtained from an extensive number of active specialists throughout Italy allow some important concluding remarks to be drawn. The main points of agreement were that multidisciplinary care teams provide many benefits but that, once the team is established, meetings and communication between members must be coordinated. Finally, the dissemination of national disease registries and the continuous updating of guidelines and position papers related to CRSwNP and comorbidities should be encouraged.

摘要:背景。慢性鼻窦炎(CRS)是一种影响鼻粘膜和副鼻窦的炎症性疾病。多达 30% 的 CRS 患者可能伴有鼻息肉病(CRSwNP 表型),而且经常与支气管哮喘相关。CRSwNP 主要表现为嗜酸性粒细胞、IgE、白细胞介素(IL)-4、IL-5 和 IL-13 参与的 2 型炎症通路的潜在激活。目前,针对这些炎症细胞因子的生物药物已被指南确认为治疗未受控制疾病的一种治疗方法。方法。作为 "ARIA-Italy "工作组活动的一部分,一个由 255 名意大利耳鼻喉科(ENT)专家、肺病专家和免疫过敏专家组成的小组积极参与了这项全国性调查,并回答了一系列问题,这些问题旨在了解患者特征描述和治疗决策的主要标准,突出多学科性,并实施 CRSwNP 患者的管理,作为精准医疗概念和生物制剂适当使用的一部分。结果。255 名专家参与了调查。结论。这项调查从意大利各地众多活跃的专家那里获得的结果可以得出一些重要的结论性意见。一致同意的要点是,多学科护理团队能带来许多益处,但团队一旦成立,就必须协调成员之间的会议和交流。最后,应鼓励传播国家疾病登记信息,不断更新与 CRSwNP 和合并症有关的指南和立场文件。
{"title":"Chronic rhinosinusitis with nasal polyposis and biological agents: the ARIA-ITALY Survey.","authors":"C Lombardi, G Passalacqua, F Menzella, R F Mauritz Canevari, G Danesi, A M Pusateri, M Carone, C Vancheri, F Di Marco, C Micheletto, G Manzotti, M Di Gioacchino, M B Bilò, M Gelardi, G Senna, G W Canonica","doi":"10.23822/EurAnnACI.1764-1489.338","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.338","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic rhinosinusitis (CRS) is an inflammatory disease that affects the nasal mucosa and the paranasal sinuses. CRS can be associated by nasal polyposis (CRSwNP phenotype) in up to 30% of patients and it is frequently associated with bronchial asthma. CRSwNP shows predominantly an underlying activation of type 2 inflammatory pathways with the involvement of eosinophils, IgE, interleukin (IL)-4, IL-5 and IL-13. Biological drugs that target these inflammatory cytokines are currently a therapeutic option recognized by guidelines for the treatment of uncontrolled form of the disease. <b>Methods.</b> As part of the activity of the \"ARIA-Italy\" working group, a panel of 255 Italian Ear, Nose and Throat (ENT) specialists, pneumologists and immuno-allergologists actively participated in this national survey and answered a series of questions geared toward understanding the main criteria for patient characterization and therapeutic decision, highlighting multidisciplinarity, and the implementation of the management of CRSwNP patients, as a part of the precision medicine concept and the appropriate use of the biologicals. <b>Results.</b> Two hundred and fifty-five experts and specialists participated in the survey. <b>Conclusions.</b> The results of this survey obtained from an extensive number of active specialists throughout Italy allow some important concluding remarks to be drawn. The main points of agreement were that multidisciplinary care teams provide many benefits but that, once the team is established, meetings and communication between members must be coordinated. Finally, the dissemination of national disease registries and the continuous updating of guidelines and position papers related to CRSwNP and comorbidities should be encouraged.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140293248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study. 自体血清皮试 (ASST) 预测慢性自发性荨麻疹患者对抗 IgE 治疗的反应:一项前瞻性研究。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-14 DOI: 10.23822/EurAnnACI.1764-1489.337
A Palladino, F Villani, E Pinter, M Visentini, R Asero

Summary: Background. Chronic spontaneous urticaria (CSU), characterized by recurrent itchy wheals and angioedema for > 6 weeks, is a quite common disease that may heavily impair the quality of life. Omalizumab, an anti-IgE mAb, has much improved the management of CSU but patients' response to the drug may vary and predictive markers are still largely missing. We investigated the predictive value of the autologous serum skin test (ASST) on omalizumab response. Methods. 15 patients with severe CSU eligible for omalizumab treatment were prospectively studied submitting them to ASST and to complete blood count, D-dimer, anti-thyroid peroxidase antibodies, and total IgE measurement before the start of the treatment. Results. 14/15 (93%) responded brilliantly to omalizumab at 3 months assessment. 7 responded in less than 1 month ("early responders") and 7 only after multiple administrations ("late responders"). Of 9 patients scoring positive on ASST, 7 (78%) were late, and 2 (22%) early responders to omalizumab (p = 0.021). Of 6 patients scoring negative on ASST, 5 were early omalizumab responders and 1 did not respond. The PPV and NPV of the ASST for a "late" response to omalizumab were 78% and 100%, respectively. Total IgE were significantly higher in early responders. Conclusions. Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.

摘要:背景。慢性自发性荨麻疹(CSU)的特点是反复发作的瘙痒性喘鸣和血管性水肿,持续时间超过 6 周,是一种相当常见的疾病,可能严重影响患者的生活质量。抗 IgE mAb 奥马珠单抗(Omalizumab)大大改善了 CSU 的治疗效果,但患者对该药物的反应可能各不相同,而预测性指标在很大程度上仍然缺失。我们研究了自体血清皮试(ASST)对奥马珠单抗反应的预测价值。研究方法对符合奥马珠单抗治疗条件的15例重症CSU患者进行了前瞻性研究,让他们在开始治疗前接受ASST和全血细胞计数、D-二聚体、抗甲状腺过氧化物酶抗体和总IgE测定。结果显示在3个月的评估中,14/15(93%)名患者对奥马珠单抗反应良好。其中 7 人在不到 1 个月的时间内就出现了反应("早期反应者"),7 人在多次用药后才出现反应("晚期反应者")。在 ASST 阳性的 9 名患者中,7 人(78%)对奥马珠单抗反应较晚,2 人(22%)反应较早(p = 0.021)。在 ASST 得分为阴性的 6 名患者中,5 名是奥马珠单抗早期应答者,1 名没有应答。ASST对奥马珠单抗 "晚期 "反应的PPV和NPV分别为78%和100%。早期应答者的总 IgE 明显较高。结论。尽管需要更大规模的前瞻性研究来证实这些结果,但本研究证实了之前的回顾性调查,即 ASST 阳性似乎可预测 CSU 患者对奥马珠单抗的缓慢反应。
{"title":"The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study.","authors":"A Palladino, F Villani, E Pinter, M Visentini, R Asero","doi":"10.23822/EurAnnACI.1764-1489.337","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.337","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Chronic spontaneous urticaria (CSU), characterized by recurrent itchy wheals and angioedema for > 6 weeks, is a quite common disease that may heavily impair the quality of life. Omalizumab, an anti-IgE mAb, has much improved the management of CSU but patients' response to the drug may vary and predictive markers are still largely missing. We investigated the predictive value of the autologous serum skin test (ASST) on omalizumab response. <b>Methods.</b> 15 patients with severe CSU eligible for omalizumab treatment were prospectively studied submitting them to ASST and to complete blood count, D-dimer, anti-thyroid peroxidase antibodies, and total IgE measurement before the start of the treatment. <b>Results.</b> 14/15 (93%) responded brilliantly to omalizumab at 3 months assessment. 7 responded in less than 1 month (\"early responders\") and 7 only after multiple administrations (\"late responders\"). Of 9 patients scoring positive on ASST, 7 (78%) were late, and 2 (22%) early responders to omalizumab (p = 0.021). Of 6 patients scoring negative on ASST, 5 were early omalizumab responders and 1 did not respond. The PPV and NPV of the ASST for a \"late\" response to omalizumab were 78% and 100%, respectively. Total IgE were significantly higher in early responders. <b>Conclusions.</b> Although larger prospective studies are needed to confirm these results, this study confirms previous retrospective investigations that the positive ASST appears to predict a slow response to omalizumab in CSU patients.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in egg allergy: a retrospective look at the utility of cut-off values. 鸡蛋过敏的挑战:对临界值效用的回顾性研究。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-14 DOI: 10.23822/EurAnnACI.1764-1489.336
P Botelho Alves, H Pires Pereira, I Carrapatoso, G Loureiro, I Farinha, M Lucena, T Freitas, A Todo Bom
{"title":"Challenges in egg allergy: a retrospective look at the utility of cut-off values.","authors":"P Botelho Alves, H Pires Pereira, I Carrapatoso, G Loureiro, I Farinha, M Lucena, T Freitas, A Todo Bom","doi":"10.23822/EurAnnACI.1764-1489.336","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.336","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140119168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Food-dependent exercise-induced allergic reactions in Lipid Transfer Protein (LTP) hypersensitive subjects: new data and a critical reappraisal. 脂质转移蛋白(LTP)过敏受试者的食物依赖性运动诱发过敏反应:新数据和批判性再评价。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-06 DOI: 10.23822/EurAnnACI.1764-1489.334
E Scala, V Villella, R Asero

Summary: Background. Lipid transfer protein is the main cause of both primary food allergy and food-dependent exercise-induced allergic reactions (FDEIAR) in Italy. What characterizes LTP-hypersensitive patients with FDEIAR is still unclear. We investigated the key characteristics of LTP-hypersensitive patients with or without FDEIAR in a large cohort of individuals sensitized to this allergen. Methods. 1,203 food-allergic patients, diagnosed on the basis of unequivocal clinical history and presence of circulating food allergen-specific IgE were studied. Serum IgE reactivity was assessed using the Allergen ExplorerALEX® system (Macroarray Diagnostics, Vienna, Austria). Association of specific IgE reactivities with FDEIAR was investigated, and patients with and without FDEIAR sensitized to LTP were compared. Results. 116 subjects (9.6%) had FDEIAR. Among these, 77 (66.3%) were LTP-reactors and 16 (13.8%) were sensitized to Tri a 19 (omega-5-gliadin). Different LTPs and omega-5-gliadin emerged as the sole allergens clearly associated with FDEIAR. Severity of allergic reactions was paralleled the level of specific IgE to LTPs. Patients with FDEIAR showed significantly lower IgE levels than their counterparts with food allergy at rest, and displayed nearly identical IgE levels regardless of the severity of allergic reactions induced by exercise. Conclusions. FDEIAR are associated with specific allergens. Specific IgE levels in LTP-hypersensitive patients with FDEIAR show an intermediate titer between those simply sensitized and those showing classic food allergy.

摘要:背景。在意大利,脂质转移蛋白是引起原发性食物过敏和食物依赖性运动诱发过敏反应(FDEIAR)的主要原因。对脂质转移蛋白过敏的 FDEIAR 患者的特征尚不清楚。我们在一大批对这种过敏原过敏的人群中调查了对 LTP 过敏或未对 FDEIAR 过敏的患者的主要特征。研究方法我们对 1203 名食物过敏患者进行了研究,这些患者根据明确的临床病史和循环中食物过敏原特异性 IgE 的存在而被确诊。使用 Allergen ExplorerALEX® 系统(Macroarray Diagnostics,奥地利维也纳)评估血清 IgE 反应性。研究了特异性 IgE 反应性与 FDEIAR 的关系,并比较了对 LTP 过敏的 FDEIAR 患者和未对 LTP 过敏的 FDEIAR 患者。结果显示116 名受试者(9.6%)患有 FDEIAR。其中 77 人(66.3%)为 LTP 反应者,16 人(13.8%)对 Tri a 19(ω-5-花生蛋白)过敏。不同的 LTP 和欧米伽-5-花生蛋白是与 FDEIAR 明显相关的唯一过敏原。过敏反应的严重程度与 LTPs 的特异性 IgE 水平相当。FDEIAR 患者在休息时的 IgE 水平明显低于食物过敏患者,而且无论运动诱发过敏反应的严重程度如何,患者的 IgE 水平几乎相同。结论。FDEIAR 与特异性过敏原有关。患有 FDEIAR 的 LTP 过敏症患者的特异性 IgE 水平介于单纯过敏症患者和典型食物过敏症患者之间。
{"title":"Food-dependent exercise-induced allergic reactions in Lipid Transfer Protein (LTP) hypersensitive subjects: new data and a critical reappraisal.","authors":"E Scala, V Villella, R Asero","doi":"10.23822/EurAnnACI.1764-1489.334","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.334","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Lipid transfer protein is the main cause of both primary food allergy and food-dependent exercise-induced allergic reactions (FDEIAR) in Italy. What characterizes LTP-hypersensitive patients with FDEIAR is still unclear. We investigated the key characteristics of LTP-hypersensitive patients with or without FDEIAR in a large cohort of individuals sensitized to this allergen. <b>Methods.</b> 1,203 food-allergic patients, diagnosed on the basis of unequivocal clinical history and presence of circulating food allergen-specific IgE were studied. Serum IgE reactivity was assessed using the Allergen ExplorerALEX<sup>®</sup> system (Macroarray Diagnostics, Vienna, Austria). Association of specific IgE reactivities with FDEIAR was investigated, and patients with and without FDEIAR sensitized to LTP were compared. <b>Results.</b> 116 subjects (9.6%) had FDEIAR. Among these, 77 (66.3%) were LTP-reactors and 16 (13.8%) were sensitized to Tri a 19 (omega-5-gliadin). Different LTPs and omega-5-gliadin emerged as the sole allergens clearly associated with FDEIAR. Severity of allergic reactions was paralleled the level of specific IgE to LTPs. Patients with FDEIAR showed significantly lower IgE levels than their counterparts with food allergy at rest, and displayed nearly identical IgE levels regardless of the severity of allergic reactions induced by exercise. <b>Conclusions.</b> FDEIAR are associated with specific allergens. Specific IgE levels in LTP-hypersensitive patients with FDEIAR show an intermediate titer between those simply sensitized and those showing classic food allergy.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Omega 5-gliadin allergy in patients with recurrent acute urticaria. 复发性急性荨麻疹患者的欧米伽 5-麸质过敏症。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-06 DOI: 10.23822/EurAnnACI.1764-1489.335
C M Rossi, M V Lenti, S Merli, G Achilli, A di Sabatino
{"title":"Omega 5-gliadin allergy in patients with recurrent acute urticaria.","authors":"C M Rossi, M V Lenti, S Merli, G Achilli, A di Sabatino","doi":"10.23822/EurAnnACI.1764-1489.335","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.335","url":null,"abstract":"","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140038975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The clinical and laboratory findings of infants with atopic dermatitis during diagnosis and follow-up. 特应性皮炎婴儿在诊断和随访期间的临床和实验室检查结果。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-01 Epub Date: 2023-01-13 DOI: 10.23822/EurAnnACI.1764-1489.281
A Chousein, H Duman Senol, E Ece Özdoğru, S Eren Akarcan, T Tuncel

Summary: Background. Atopic dermatitis is a chronic disease that affects patient and parents life worsely. What time will the patient go into remission is not known. Therefore, clinical and laboratory indicators that can indicate remission are needed. Materials and Methods. The study was conducted in İzmir Health Sciences University, Tepecik Training and Research Hospital. The clinical and laboratory data of patients between January 2014 and December 2019 were scanned from the patient records and the hospital data system. Results. 102 patients with a median age of 8 (min 2- max 24) months were included in the study. The median age of onset of the symptoms was 3 (min 1-max 21) months. The patients most frequently (85.2%) presented with eczema and lesions were most common (60.7%) in the extremities. Most of the patients (56.9%) had mild dermatitis. In the 6th month, 26.5% who continued follow-up had clinical improvement. Food allergy was present in 33.3% of the patients. The most common food allergen was egg (52.9%). Food allergy was associated with the severity of atopic dermatitis (p = 0.033), and the symptoms started earlier (p = 0.002). There is no relationship between the severity of atopic dermatitis and gender, family history, presence of additional atopic disease, response to treatment, total IgE and eosinophil count (p > 0.05); however, it was determined that the symptoms started earlier in patients with moderate/severe atopic dermatitis (p = 0.002). Conclusions. Food allergy is more common in the early-onset and moderate/severe atopic dermatitis. Accurate diagnosis of food allergy is necessary to increase the success of treatment and to prevent unnecessary diets.

摘要:目的。本研究旨在探讨 0-2 岁特应性皮炎患儿入院时的临床和实验室检查结果与随访预后之间的关系。材料和方法。研究在伊兹密尔健康科学大学泰佩契克培训与研究医院进行。研究人员从患者病历和医院数据系统中扫描了患者在2014年1月至2019年12月期间的临床和实验室数据。研究结果研究共纳入102名患者,中位年龄为8(9)(最小2-最大24)个月。发病年龄中位数为3(5)(最小1-最大21)个月。患者最常(85.2%)出现湿疹,皮损最常(60.7%)出现在四肢。大多数患者(56.9%)有轻度皮炎。第 6 个月时,继续随访的 26.5%患者的临床症状有所改善。33.3%的患者对食物过敏。最常见的食物过敏原是鸡蛋(52.9%)。食物过敏与特应性皮炎的严重程度有关(p = 0.033),而且症状开始得更早(p = 0.002)。特应性皮炎的严重程度与性别、家族史、是否患有其他特应性疾病、对治疗的反应、总 IgE 和嗜酸性粒细胞计数之间没有关系(p > 0.05);但是,中度/重度特应性皮炎患者的症状开始得较早(p = 0.002)。结论食物过敏在早期和中度/重度特应性皮炎中更为常见。要提高治疗的成功率,避免不必要的饮食,就必须准确诊断食物过敏。
{"title":"The clinical and laboratory findings of infants with atopic dermatitis during diagnosis and follow-up.","authors":"A Chousein, H Duman Senol, E Ece Özdoğru, S Eren Akarcan, T Tuncel","doi":"10.23822/EurAnnACI.1764-1489.281","DOIUrl":"10.23822/EurAnnACI.1764-1489.281","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Atopic dermatitis is a chronic disease that affects patient and parents life worsely. What time will the patient go into remission is not known. Therefore, clinical and laboratory indicators that can indicate remission are needed. <b>Materials and Methods.</b> The study was conducted in İzmir Health Sciences University, Tepecik Training and Research Hospital. The clinical and laboratory data of patients between January 2014 and December 2019 were scanned from the patient records and the hospital data system. <b>Results.</b> 102 patients with a median age of 8 (min 2- max 24) months were included in the study. The median age of onset of the symptoms was 3 (min 1-max 21) months. The patients most frequently (85.2%) presented with eczema and lesions were most common (60.7%) in the extremities. Most of the patients (56.9%) had mild dermatitis. In the 6<sup>th</sup> month, 26.5% who continued follow-up had clinical improvement. Food allergy was present in 33.3% of the patients. The most common food allergen was egg (52.9%). Food allergy was associated with the severity of atopic dermatitis (p = 0.033), and the symptoms started earlier (p = 0.002). There is no relationship between the severity of atopic dermatitis and gender, family history, presence of additional atopic disease, response to treatment, total IgE and eosinophil count (p > 0.05); however, it was determined that the symptoms started earlier in patients with moderate/severe atopic dermatitis (p = 0.002). <b>Conclusions.</b> Food allergy is more common in the early-onset and moderate/severe atopic dermatitis. Accurate diagnosis of food allergy is necessary to increase the success of treatment and to prevent unnecessary diets.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"71-78"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9072719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acetylsalicylic acid desensitization in an allergic pregnant woman post-vascular scaffolds implantation. 血管支架植入术后过敏性孕妇的乙酰水杨酸(ASA)脱敏。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-01 Epub Date: 2022-12-13 DOI: 10.23822/EurAnnACI.1764-1489.276
F Rivolta, A Chiei Gallo, A Sangalli, V Pravettoni

Summary: The use of acetylsalicylic acid (ASA) desensitization for patients with coronary artery disease (CAD) is growing, but no data are available on desensitization protocol in patients with ASA sensitivity and CAD during pregnancy. This case report shows that ASA desensitization protocol during pregnancy could be safe and effective in a tertiary centre with a multidisciplinary team.

摘要:冠状动脉疾病(CAD)患者使用乙酰水杨酸(ASA)脱敏治疗的情况越来越多,但目前还没有关于妊娠期对 ASA 敏感且患有 CAD 的患者脱敏治疗方案的数据。本病例报告显示,在一个拥有多学科团队的三级医疗中心,妊娠期ASA脱敏方案可能是安全有效的。
{"title":"Acetylsalicylic acid desensitization in an allergic pregnant woman post-vascular scaffolds implantation.","authors":"F Rivolta, A Chiei Gallo, A Sangalli, V Pravettoni","doi":"10.23822/EurAnnACI.1764-1489.276","DOIUrl":"10.23822/EurAnnACI.1764-1489.276","url":null,"abstract":"<p><strong>Summary: </strong>The use of acetylsalicylic acid (ASA) desensitization for patients with coronary artery disease (CAD) is growing, but no data are available on desensitization protocol in patients with ASA sensitivity and CAD during pregnancy. This case report shows that ASA desensitization protocol during pregnancy could be safe and effective in a tertiary centre with a multidisciplinary team.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"86-88"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10705431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current update on anaphylaxis: anaphylaxis management in recent guidelines. 过敏反应的最新进展:最近指南中的过敏反应管理。
IF 2.3 Q2 ALLERGY Pub Date : 2024-03-01 Epub Date: 2023-07-18 DOI: 10.23822/EurAnnACI.1764-1489.306
D Antolín-Amérigo, C Vidal-Albareda, D González de Olano, B de la Hoz-Caballer

Summary: Anaphylaxis is a potentially fatal hypersensitivity reaction but frequently underrecognized. Although its incidence rates vary according to geographical location, it seems clear that there has been a general increase in recent years, either because of greater recognition of this entity or because it is progressing proportionally to the presence of allergic diseases in the world. The development of anaphylaxis management guidelines adapted to local or regional needs seems of utmost importance. Furthermore, it is necessary to assess their implementation and their positive effect regarding diagnosing and treating anaphylaxis. In this review we explore the currently existing definitions of anaphylaxis and its epidemiology, the potential triggers of anaphylaxis and guideline recommendations in terms of diagnosis and management, proposing a novel anaphylaxis calculator and reviewing the current scoring methods for anaphylactic episodes.

摘要:过敏反应是一种潜在的致命超敏反应,但经常被低估。尽管其发病率因地理位置而异,但很明显,近年来发病率普遍上升,要么是因为人们对这一实体的认识加深,要么是由于它的发展与世界上过敏性疾病的存在成比例。制定适应当地或地区需求的过敏反应管理指南似乎至关重要。此外,有必要评估其实施情况及其在诊断和治疗过敏反应方面的积极作用。在这篇综述中,我们探讨了过敏反应的现有定义及其流行病学、过敏反应的潜在诱因以及诊断和管理方面的指南建议,提出了一种新的过敏反应计算器,并回顾了当前过敏事件的评分方法。
{"title":"Current update on anaphylaxis: anaphylaxis management in recent guidelines.","authors":"D Antolín-Amérigo, C Vidal-Albareda, D González de Olano, B de la Hoz-Caballer","doi":"10.23822/EurAnnACI.1764-1489.306","DOIUrl":"10.23822/EurAnnACI.1764-1489.306","url":null,"abstract":"<p><strong>Summary: </strong>Anaphylaxis is a potentially fatal hypersensitivity reaction but frequently underrecognized. Although its incidence rates vary according to geographical location, it seems clear that there has been a general increase in recent years, either because of greater recognition of this entity or because it is progressing proportionally to the presence of allergic diseases in the world. The development of anaphylaxis management guidelines adapted to local or regional needs seems of utmost importance. Furthermore, it is necessary to assess their implementation and their positive effect regarding diagnosing and treating anaphylaxis. In this review we explore the currently existing definitions of anaphylaxis and its epidemiology, the potential triggers of anaphylaxis and guideline recommendations in terms of diagnosis and management, proposing a novel anaphylaxis calculator and reviewing the current scoring methods for anaphylactic episodes.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":"51-64"},"PeriodicalIF":2.3,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9817806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the origin and educational quality of youtube videos on adrenaline auto-ınjectors. 评估有关肾上腺素自动注射器的youtube视频的来源和教育质量。
IF 2.3 Q2 ALLERGY Pub Date : 2024-02-20 DOI: 10.23822/EurAnnACI.1764-1489.333
I D Toprak, P Korkmaz, Z Kılınc, D Unal, S Demir, A Gelincik

Summary: Background. Guidelines highlight the pivotal role of adrenaline auto-injector (AAI) training. However, the standards of visual training platforms has not been determined. Our aim was to evaluate the reliability and quality of the AAI related videos on YouTube. Methods. After a search on YouTube about AAI, all videos were categorized into groups based on their origin and the aim of the content. The quality, reliability, understandibility, and actionability of the videos were evaluated using the Global Quality Scale (GQS), Patient Education Materials Assessment Tool Audovisiual (PEMAT-A/V), Quality Criteria for Consumer Health Information (DISCERN), and a modified DISCERN. In each video, the application steps of AAI were evaluated according to a scale of correct usage. Results. 107 YouTube videos in English were included. No significant difference in terms of views, likes, duration and uploading time was observed between the health and non-health groups whereas the GQS (p=0.001), DISCERN (total: p=0.02, and overall: p=0.094), modified DISCERN (p=0.001) scores were higher in the health group. It was found that scores tended to be higher in educational videos. AAI use was mentioned in 85% videos. The median number of mentioned steps was 6. Conclusions. YouTube is an effective platform for visual learning for the use of AAIs. Although the visibility of the videos is equal independent of the origin, the ones recorded by medical professionals seem to provide the most qualified and reliable information.

摘要:背景。指南强调了肾上腺素自动注射器 (AAI) 培训的关键作用。然而,视觉培训平台的标准尚未确定。我们的目的是评估 YouTube 上与 AAI 相关视频的可靠性和质量。方法在 YouTube 上搜索有关 AAI 的视频后,根据其来源和内容目的将所有视频分为几组。使用全球质量量表(GQS)、患者教育材料评估工具(PEMAT-A/V)、消费者健康信息质量标准(DISCERN)和修改后的 DISCERN 对视频的质量、可靠性、可理解性和可操作性进行评估。在每段视频中,AAI 的应用步骤都根据正确使用程度进行评估。结果共收录了 107 个 YouTube 英文视频。健康组和非健康组在观看次数、点赞数、持续时间和上传时间方面没有明显差异,而健康组的 GQS(p=0.001)、DISCERN(总分:p=0.02,总分:p=0.094)和修改后的 DISCERN(p=0.001)得分更高。研究发现,教育视频的得分往往更高。85%的视频提到了 AAI 的使用。提及步骤的中位数为 6。YouTube 是使用 AAI 进行视觉学习的有效平台。虽然视频的可见度与来源无关,但由医学专业人员录制的视频似乎提供了最合格、最可靠的信息。
{"title":"Evaluation of the origin and educational quality of youtube videos on adrenaline auto-ınjectors.","authors":"I D Toprak, P Korkmaz, Z Kılınc, D Unal, S Demir, A Gelincik","doi":"10.23822/EurAnnACI.1764-1489.333","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.333","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Guidelines highlight the pivotal role of adrenaline auto-injector (AAI) training. However, the standards of visual training platforms has not been determined. Our aim was to evaluate the reliability and quality of the AAI related videos on YouTube. <b>Methods.</b> After a search on YouTube about AAI, all videos were categorized into groups based on their origin and the aim of the content. The quality, reliability, understandibility, and actionability of the videos were evaluated using the Global Quality Scale (GQS), Patient Education Materials Assessment Tool Audovisiual (PEMAT-A/V), Quality Criteria for Consumer Health Information (DISCERN), and a modified DISCERN. In each video, the application steps of AAI were evaluated according to a scale of correct usage. <b>Results.</b> 107 YouTube videos in English were included. No significant difference in terms of views, likes, duration and uploading time was observed between the health and non-health groups whereas the GQS (p=0.001), DISCERN (total: p=0.02, and overall: p=0.094), modified DISCERN (p=0.001) scores were higher in the health group. It was found that scores tended to be higher in educational videos. AAI use was mentioned in 85% videos. The median number of mentioned steps was 6. <b>Conclusions.</b> YouTube is an effective platform for visual learning for the use of AAIs. Although the visibility of the videos is equal independent of the origin, the ones recorded by medical professionals seem to provide the most qualified and reliable information.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of patch testing based in clinical response to contact allergen restrictions in allergic contact dermatitis. 根据过敏性接触性皮炎患者对接触过敏原限制的临床反应进行斑贴测试的诊断准确性。
IF 2.3 Q2 ALLERGY Pub Date : 2024-02-20 DOI: 10.23822/EurAnnACI.1764-1489.331
J Sánchez, L Álvarez, S Die, J Miquel-Miquel, M Velásquez

Summary: Background. Patch testing (PT) is used to identify substances that cause allergic contact dermatitis (ACD). However, the clinical effects of allergen restrictions following PT have not been thoroughly investigated. This study aims to assess the diagnostic accuracy of PT in patients suspected of having ACD. Methods. Prospective study. PT were performed in patients with clinical diagnosis of ACD. Patients with a positive PT (case group) had a strict restriction of the suspected substance for one month. In patients with negative patch testing (control group), allergen restriction was based in clinical history. Clinical reduction (CR) of at least 50% in disease activity (CR50%) after one month of allergen restriction was considered clinically relevant. Total control was defined as clinical reduction of at least 90% (CR90%). Results. From 400 patients, 66.2% had a positive PT. The sensitivity of PT to identify CR50% was 84%, specificity 47%, PPV 53%, and NPV 81%. Only 10.5% of patients achieved CR90%. Conclusions. The PT had moderate diagnostic accuracy. It could be useful as a screening, but a positive result should be confirmed with controlled allergen restriction. The low number of patients who achieved a 90% CR invites to reconsider the allergens included in PT and the mechanistic processes of the disease.

摘要:背景。斑贴试验(PT)用于确定导致过敏性接触性皮炎(ACD)的物质。然而,对过敏原限制后的临床效果尚未进行深入研究。本研究旨在评估贴片测试对疑似 ACD 患者的诊断准确性。方法:前瞻性研究。前瞻性研究。对临床诊断为 ACD 的患者进行 PT 检查。PT阳性的患者(病例组)在一个月内严格禁用可疑物质。斑贴试验阴性的患者(对照组)则根据临床病史限制使用过敏原。在限制过敏原一个月后,疾病活动的临床缓解(CR)至少达到 50%(CR50%)即为临床相关性。完全控制的定义是临床活动至少减少 90% (CR90%)。结果在 400 名患者中,66.2% 的患者 PT 呈阳性。PT 鉴定 CR50% 的灵敏度为 84%,特异性为 47%,PPV 为 53%,NPV 为 81%。只有 10.5% 的患者达到 CR90%。结论。PT 具有中等诊断准确性。它可作为筛查手段,但阳性结果应通过控制过敏原限制来确认。达到 90% CR 值的患者人数较少,这就需要重新考虑 PT 所包含的过敏原和疾病的机理过程。
{"title":"Diagnostic accuracy of patch testing based in clinical response to contact allergen restrictions in allergic contact dermatitis.","authors":"J Sánchez, L Álvarez, S Die, J Miquel-Miquel, M Velásquez","doi":"10.23822/EurAnnACI.1764-1489.331","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.331","url":null,"abstract":"<p><strong>Summary: </strong><b>Background.</b> Patch testing (PT) is used to identify substances that cause allergic contact dermatitis (ACD). However, the clinical effects of allergen restrictions following PT have not been thoroughly investigated. This study aims to assess the diagnostic accuracy of PT in patients suspected of having ACD. <b>Methods.</b> Prospective study. PT were performed in patients with clinical diagnosis of ACD. Patients with a positive PT (case group) had a strict restriction of the suspected substance for one month. In patients with negative patch testing (control group), allergen restriction was based in clinical history. Clinical reduction (CR) of at least 50% in disease activity (CR50%) after one month of allergen restriction was considered clinically relevant. Total control was defined as clinical reduction of at least 90% (CR90%). <b>Results.</b> From 400 patients, 66.2% had a positive PT. The sensitivity of PT to identify CR50% was 84%, specificity 47%, PPV 53%, and NPV 81%. Only 10.5% of patients achieved CR90%. <b>Conclusions.</b> The PT had moderate diagnostic accuracy. It could be useful as a screening, but a positive result should be confirmed with controlled allergen restriction. The low number of patients who achieved a 90% CR invites to reconsider the allergens included in PT and the mechanistic processes of the disease.</p>","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139905331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European annals of allergy and clinical immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1